Moomoo AIのまとめ
Aclarion, Inc. reported its financial results for the quarter ended March 31, 2024, with a revenue of $10,114, a decrease from the previous year's $25,470. The company experienced a gross loss of $9,362 compared to a gross profit of $8,017 in the same quarter of the previous year. Operating expenses totaled $1,265,945, with sales and marketing at $181,056, research and development at $239,042, and general and administrative expenses at $845,847. The net loss for the quarter was $2,399,102, a larger loss than the $1,183,460 reported in the same period last year. The company completed a public offering, raising approximately $3.0 million before expenses, and also raised about $1.4 million from an equity line. As of March 31, 2024, Aclarion had cash, including restricted cash, of $2,142,635. The company's management believes that current funds will be sufficient to support operations into the third quarter of 2024. Aclarion is focused on leveraging magnetic resonance spectroscopy (MRS) and a proprietary biomarker to optimize clinical treatments. The company is also working on improving its internal control over financial reporting and addressing material weaknesses identified in its disclosure controls and procedures.
Aclarion, Inc. reported its financial results for the quarter ended March 31, 2024, with a revenue of $10,114, a decrease from the previous year's $25,470. The company experienced a gross loss of $9,362 compared to a gross profit of $8,017 in the same quarter of the previous year. Operating expenses totaled $1,265,945, with sales and marketing at $181,056, research and development at $239,042, and general and administrative expenses at $845,847. The net loss for the quarter was $2,399,102, a larger loss than the $1,183,460 reported in the same period last year. The company completed a public offering, raising approximately $3.0 million before expenses, and also raised about $1.4 million from an equity line. As of March 31, 2024, Aclarion had cash, including restricted cash, of $2,142,635. The company's management believes that current funds will be sufficient to support operations into the third quarter of 2024. Aclarion is focused on leveraging magnetic resonance spectroscopy (MRS) and a proprietary biomarker to optimize clinical treatments. The company is also working on improving its internal control over financial reporting and addressing material weaknesses identified in its disclosure controls and procedures.
Aclarion社は、2024年3月31日終了の四半期の財務結果を報告し、売上高が10,114ドルと前年の25,470ドルから減少しました。同四半期に粗利益8,017ドルに対し、9,362ドルの粗損失を被りました。営業費用は総額1,265,945ドルで、その内訳は、営業とマーケティングが181,056ドル、研究開発が239,042ドル、一般および管理費用が845,847ドルでした。今期の純損失は、昨年同期報告の1,183,460ドルよりも大きな2,399,102ドルでした。同社は公開募集を実施し、総額約3.0百万ドルを調達し、また、株式ラインから約1.4百万ドルを調達しました。2024年3月3...すべて展開
Aclarion社は、2024年3月31日終了の四半期の財務結果を報告し、売上高が10,114ドルと前年の25,470ドルから減少しました。同四半期に粗利益8,017ドルに対し、9,362ドルの粗損失を被りました。営業費用は総額1,265,945ドルで、その内訳は、営業とマーケティングが181,056ドル、研究開発が239,042ドル、一般および管理費用が845,847ドルでした。今期の純損失は、昨年同期報告の1,183,460ドルよりも大きな2,399,102ドルでした。同社は公開募集を実施し、総額約3.0百万ドルを調達し、また、株式ラインから約1.4百万ドルを調達しました。2024年3月31日の時点で、Aclarion社は制限付き現金を含む現金が2,142,635ドルあります。同社の経営陣は、現在の資金が2024年第3四半期までの運営を支援するのに十分であると信じています。Aclarion社は、磁気共鳴分光法（MRS）と独自のバイオマーカーを利用して臨床治療を最適化することを目的としています。同社はまた、財務報告の内部統制を改善し、開示コントロールおよび手順で特定された重要な問題に対処するための取り組みを進めています。
役に立った
役に立たない
